Management of Cutaneous Angiosarcoma: an Update Review

Area of Science:

• Oncology
• Dermatology
• Surgical Oncology

Background:

• Cutaneous angiosarcoma (cAS) is a rare, aggressive vascular malignancy.
• Local invasion is a characteristic feature of cAS, complicating surgical management.
• Current treatment paradigms are evolving, with increasing interest in multimodal approaches.

Purpose of the Study:

• To review and summarize current treatment strategies for cutaneous angiosarcoma.
• To highlight the role of surgery, radiotherapy, and chemotherapy in managing cAS.
• To discuss emerging therapeutic options for advanced or resistant disease.

Main Methods:

• Literature review of studies on cutaneous angiosarcoma treatment.
• Analysis of established and investigational therapeutic regimens.
• Synthesis of evidence regarding surgical, radiotherapeutic, and chemotherapeutic interventions.

Main Results:

• Wide-margin excision is recommended for localized cAS.
• Preoperative and postoperative radiotherapy are suggested due to cAS's invasive nature.
• Neoadjuvant therapies may enable less extensive surgical procedures.
• Radiotherapy or chemoradiotherapy are options for unresectable metastatic cAS.
• Paclitaxel is a recognized first-line chemotherapy.
• Targeted agents and immunotherapy are being investigated for taxane-resistant tumors.

Conclusions:

• Multimodal treatment, including surgery and radiotherapy, is crucial for cAS.
• Neoadjuvant and adjuvant therapies play a significant role in optimizing surgical outcomes and managing local invasion.
• Ongoing research into novel agents offers hope for patients with refractory or metastatic cAS.